PLEASANTON, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” “HCTI” or the “Company”), In a pioneering move, a leading health system has partnered with Healthcare Triangle to utilize a groundbreaking cloud-based AI and machine learning solution. This collaboration establishes a revolutionary benchmark in the management and utilization of patient data, ultimately elevating the standards for enhanced care delivery.
The deployment of an advanced AI solution of readabl.ai that automates the categorization and matching of crucial patient information from diverse unstructured data sources. By leveraging Healthcare Triangle’s expertise in artificial intelligence and machine learning, the system adeptly identifies and extracts vital data from documents, faxes, and narrative reports. This innovative approach not only streamlines efficiency and enhances the value from document processing but also significantly accelerates the provision of critical information to healthcare providers, thus elevating patient care quality.
A hallmark of this collaboration is Healthcare Triangle’s development of an unparalleled AI model that actively learns from real-time healthcare data. This model’s continuous evolution through real-time learning marks a significant leap in AI application within healthcare. Further expanding its technological frontier, Healthcare Triangle has announced plans to integrate this AI model with Large Language Models (LLMs), enhancing its capabilities to understand and process natural language on an unprecedented scale. This integration is poised to offer even more sophisticated insights and processing abilities, making it a potent tool for healthcare organizations.
Moreover, this cutting-edge technology, including its LLM integration, is now accessible to other healthcare organizations. This initiative not only cements the health system’s position as a vanguard of innovative patient care but also democratizes access to state-of-the-art AI technology across the healthcare sector.
Key Achievements through this collaboration Include:
The collaboration between the health system and Healthcare Triangle, especially the innovative integration of the AI model with LLMs, signifies a monumental advancement in healthcare technology. It exemplifies a shared commitment to harnessing technological innovations to not only improve patient outcomes and operational efficiencies but also to pave the way for a new era of data-driven healthcare.
“By making these advanced technologies available to a broader spectrum of healthcare providers, we are setting the stage for a revolutionary shift in the healthcare industry. The integration of our AI model with Large Language Models is a game-changer, allowing us to process and understand patient data in ways it was never thought possible,” stated Anand Kumar, Interim CEO at Healthcare Triangle.
This groundbreaking initiative underscores a pivotal moment in healthcare, highlighting a commitment to technological innovation for superior health outcomes and operational excellence across the healthcare industry.
About Healthcare Triangle
Healthcare Triangle, Inc. based in Pleasanton, California, reinforces healthcare progress through breakthrough technology and extensive industry knowledge and expertise. We support healthcare including hospitals and health systems, payers, and pharma/life sciences organizations in their effort to improve health outcomes through better utilization of the data and information technologies that they rely on. Healthcare Triangle achieves HITRUST Certification for Cloud and Data Platform (CaDP), marketed as CloudEzTM, DataEzTM, and readabl.AI. HITRUST Risk-based, 2-year (r2) Certified status demonstrates to our clients the highest standards for data protection and information security. Healthcare Triangle enables the adoption of new technologies, data enlightenment, business agility, and response to immediate business needs and competitive threats. The highly regulated healthcare and life sciences industries rely on Healthcare Triangle for expertise in digital transformation encompassing the cloud, security and compliance, identity management, data lifecycle management, healthcare interoperability, and clinical and business performance optimization. www.healthcaretriangle.com.
Forward-Looking Statements and Safe Harbor Notice
All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate.” The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company’s Annual Report on Form 10-K filed with the SEC on March 18, 2024, subsequent filings and future reports filed with the SEC. All the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.
The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.
Contacts
Investors:
1-800-617-9550
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.09 |
Daily Change: | 0.02 1.87 |
Daily Volume: | 38,816 |
Market Cap: | US$6.180M |
April 04, 2024 March 12, 2024 February 14, 2024 February 08, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB